AAV capsid bioengineering in primary human retina models

• Published in: Scientific reports Vol. 13; no. 1; p. 21946
• Main Authors: Westhaus, Adrian, Eamegdool, Steven S, Fernando, Milan, Fuller-Carter, Paula, Brunet, Alicia A, Miller, Annie L, Rashwan, Rabab, Knight, Maddison, Daniszewski, Maciej, Lidgerwood, Grace E, Pébay, Alice, Hewitt, Alex, Santilli, Giorgia, Thrasher, Adrian J, Carvalho, Livia S, Gonzalez-Cordero, Anai, Jamieson, Robyn V, Lisowski, Leszek
• Format: Journal Article
• Language: English
• Published: England Nature Publishing Group 11.12.2023; Nature Publishing Group UK; Nature Portfolio
• Subjects: Benchmarks; Bioengineering; Capsid - metabolism; Capsid Proteins - genetics; Capsid Proteins - metabolism; Capsids; Cell culture; Dependovirus - metabolism; Directed evolution; Explants; Gene therapy; Genetic Therapy; Genetic Vectors - genetics; Humans; Retina; Retina - metabolism; Transduction, Genetic; Transgenes
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-023-49112-2

Adeno-associated viral (AAV) vector-mediated retinal gene therapy is an active field of both pre-clinical as well as clinical research. As with other gene therapy clinical targets, novel bioengineered AAV variants developed by directed evolution or rational design to possess unique desirable properties, are entering retinal gene therapy translational programs. However, it is becoming increasingly evident that predictive preclinical models are required to develop and functionally validate these novel AAVs prior to clinical studies. To investigate if, and to what extent, primary retinal explant culture could be used for AAV capsid development, this study performed a large high-throughput screen of 51 existing AAV capsids in primary human retina explants and other models of the human retina. Furthermore, we applied transgene expression-based directed evolution to develop novel capsids for more efficient transduction of primary human retina cells and compared the top variants to the strongest existing benchmarks identified in the screening described above. A direct side-by-side comparison of the newly developed capsids in four different in vitro and ex vivo model systems of the human retina allowed us to identify novel AAV variants capable of high transgene expression in primary human retina cells.